In this issue:
Onset of MRI efficacy of ocrelizumab in RMS
Serum NfL in presymptomatic MS
Risk of natalizumab-associated PML in MS is reduced with extended interval dosing
Teriflunomide’s effect on humoral response to EBV and cortical gray matter pathology in MS
Discontinuation of DMT for RRMS: Effect on clinical and MRI outcomes
Illegal cannabis use among Danes with MS
Outcomes after fingolimod to alemtuzumab treatment shift in RRMS
A case of PML under DMF treatment without severe lymphopenia or immunosenescence
Reliability of self-reported walking distance for EDSS scores in MS
ADLs are more valuable than classical neurological examination to assess upper extremity function in MS
Please login below to download this issue (PDF)